Know Cancer

forgot password

Multicenter Randomized Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles

18 Years
85 Years
Open (Enrolling)
Mediastinal Tumours and Lymph Nodes, Celiac, Perigastric and Peri-pancreatic Lymph Nodes, Pancreatic Masses, Liver Masses, Adrenal Masses

Thank you

Trial Information

Multicenter Randomized Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles

Tissue acquisition by Endoscopic ultrasound plays a central role in diagnosis of several
pathologies; this is achieved by obtaining cytological material with fine needle aspiration
(FNA) needles that are able to provide smears of malignant cells. Several needles are at
present available including 19 Gauge, 22 Gauge and 25 Gauge needles. A 22 Gauge needle is at
present the standard needle and most of the EUS-FNA results are based on FNA with this

Twenty five Gauge needles presently available on the market are distinctly small, highly
flexible and may be easier to penetrate hard pancreatic tumors. There even is anecdotal
messages that this size of needle may be able to traverse relatively large vascular
structures without major risk. However, there is very scant data on whether a 25 G needle is
comparable to a standard 22 G needle in terms of specimen cellularity and quality. There is
only one small randomized trial published as an abstract by Lee et al reporting no
statistical significant difference in cellularity between the two groups of needle size as
judged by 2 different cytologists. However, the conclusion is dubious because considerable
bias may be present since both needles were used in the same lesion. There is therefore a
need for a properly designed randomized study comparing different needle sizes.

This study is a prospective randomized multicenter study. Patients referred to one of the
participating departments for an EUS examination will be included prospectively. Linear EUS
examination will be done with a linear echoendoscope for lymph nodes, mediastinal,
pancreatic and other intra-abdominal masses.

Tumor and lymph node characteristics will be carefully described: size (long axis),
echogeneity (hypoechoic, hyperechoic, mixed), and echostructure (homogenous, in-homogenous,
calcifications), shape (round, oval, triangular), border (regular, irregular).

EUS-guided cell sampling will be performed with a 22 G (Medi-Globe, Sonotip II) and 25 G
(Medi-Globe, Sonotip II) needles under EUS and Colour-Doppler guidance.

Needle order will be selected randomly, one single needle pr. Lesion. Three passes will be
performed with either of the needles after randomization, using 6 uniform to and fro
movements on every pass with continuous 10cc suction for the reason of standardization. The
material will be expelled on separate numbered glass slides. The cytopathologist will review
the material after staining blinded to the needle size and will be using standardized
criteria for evaluation of cellularity.

Doubtless, this multicenter randomized controlled trial comparison, as any other
experimental method, needs with necessity a serious statistical evaluation, bringing the
benefits of improving the reliability and credibility of the findings thus obtained.
Accordingly, both exploratory data analysis and statistical inference will be performed.
Technically, the expected number of lesions to be included in the study will be 220, 110 in
each group. Block randomization (block size = 4) will be used to ensure exactly equal
treatment numbers at certain equally spaced points in the sequence of patients assignments
(Knuth shuffle algorithm for random permutations).

For diagnostic tests the sensitivity, specificity positive and negative predictive value and
diagnostic accuracy will be calculated and calculated separately for EUS-FNA during 1st
pass, 2nd pass and 3rd pass by comparing the results with the final diagnosis. All results
will be expressed as mean, standard deviation (SD) and confidence interval. Testing
hypotheses will be used afterwards. An a priori power analysis will be performed to
determine the appropriate sample size in order to achieve adequate power for the statistical
tests subsequently used. The data from both groups will be compared by standard comparison
tests chi-square test or Fishers exact test where appropriate. The level of statistical
significance is stated as 0.05.

Inclusion Criteria:

- Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent
to the upper GI tract

- Well informed signed consent for EUS-guided FNA

Exclusion Criteria:

- Severe coagulopathy

- Uncorrectable severe platelet dysfunction

- Presence of large intervening vessels on color or power Doppler

- Failure to provide informed consent

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Value of EUS-FNA 22 Gauge needle comparing with EUS-FNA 25 Gauge needle in terms of cellularity and diagnostic yield for diagnosis of various pathologies.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

Peter Vilmann, Professor

Investigator Role:

Study Director

Investigator Affiliation:

Gentofte Hospital, Copenhagen University, Denmark


Denmark: The Danish National Committee on Biomedical Research Ethics

Study ID:




Start Date:

November 2009

Completion Date:

December 2012

Related Keywords:

  • Mediastinal Tumours and Lymph Nodes
  • Celiac, Perigastric and Peri-pancreatic Lymph Nodes
  • Pancreatic Masses
  • Liver Masses
  • Adrenal Masses
  • 22 Gauge Needle
  • 25 Gauge Needle
  • Mediastinal Neoplasms
  • Marfan Syndrome